Fei Liu is an Associate Professor in the Department of Chemistry and Biomolecular Sciences at Macquarie University, Sydney. She holds a BSc in Chemistry from John Carroll University (2001) and a PhD in Organic Chemistry from Yale University (2004). Her postdoctoral training at Harvard Medical School focused on molecular medicine and biosynthetic approaches. She joined Macquarie University in 2004 and has since led research in synthetic methodology, chemical proteomics, and drug discovery. Research Interests: Her work spans asymmetric catalysis, isozyme-specific antagonist discovery, and protein post-translational modifications. She collaborates with the Australian Proteomics Analysis Facility (APAF) to advance systems proteomics. Key Projects: Current grants include projects on degrader technology for Amyotrophic Lateral Sclerosis (MND), high-throughput electron diffractometry, and AI-driven agricultural pest monitoring. She has led 35+ research projects since 2006. Lab & Team: The Liu Research Group includes PhD candidates, postdocs, and alumni who focus on organic synthesis, proteomic tools, and bioactive molecule development. The lab’s website provides further technical details and protocols.
Simone M.J. de Jong is a Researcher in the Department of Biomedical Materials and Chemistry at the Biomedical Engineering School of Technische Universiteit Eindhoven. Her research focuses on biomaterial design for regenerative medicine applications, including cardiac tissue engineering, kidney organoid maturation, and vascular graft functionalization. She holds a Master’s degree from TU Eindhoven, where her thesis explored Notch ligand integration into supramolecular biomaterials under Prof. Dankers and Dr. Putti’s supervision. Her work combines advanced biomaterials with biological systems to enhance tissue regeneration outcomes. Recent studies include hybrid hydrogel systems for heart repair and heparin/IL-4 functionalized vascular grafts in rat models. Collaborations span disciplines like immunology and stem cell biology, with notable contributions to supramolecular platforms for bioactive protein delivery. Publications highlight her expertise in biomaterial-driven organoid maturation, macrophage polarization modulation, and functional surface engineering. Though no specific awards are listed, her work has garnered significant citations and readership across platforms like Mendeley and Scopus.
Dr Jinju Chen is a researcher at Newcastle University specializing in interdisciplinary studies at the interface of biofilm mechanics, nanomechanics, and biomedical engineering. Her work integrates experimental and computational approaches to understand microbial behavior, material interactions, and tissue engineering applications. Key research themes include biofilm formation mechanisms, surface engineering for antimicrobial coatings, and mechanosensing in biological systems. Her research combines advanced experimental techniques like atomic force microscopy with computational models such as CFD-DEM for simulating biofilm dynamics. Notable projects include developing slippery liquid-like surfaces to combat biofilm formation and analyzing bacterial cell wall adaptations under mechanical stress. Collaborations span microbiology, materials science, and robotics, with applications in medical devices and environmental biotechnology. Publications highlight achievements in: Designing anti-biofilm surfaces with long-term efficacy Characterizing novel enzymes for herbicide degradation Modeling fibroblast mechanosensing in engineered substrates Developing thermoelectric materials with tunable thermal properties Her work bridges fundamental science and translational engineering, addressing challenges in infection prevention, energy systems, and regenerative medicine.
Pasquale Cervero is a Research Fellow affiliated with the Institute of Medical Microbiology, Virology and Hygiene at the University Medical Center Hamburg-Eppendorf (UKE) , part of the University of Hamburg . His research focuses on podosome biology , cellular invasion mechanisms , and endocytic pathways . He holds a PhD (Dr. rer. nat.) and has developed computational tools like Poji for analyzing podosome structures. Key research areas include podosome dynamics in cancer metastasis, mechanosensory signaling in cells, and actin cytoskeleton regulation. His work bridges molecular mechanisms with cellular behaviors, contributing to understanding pathological processes such as tumor invasion. Publications highlight advancements in podosome lifecycle analysis, cargo-specific endocytosis, and computational methods for microscopy data. Collaborations with groups like Linder S. and Condeelis J. underscore his interdisciplinary approach to cell biology.
David Bilder is a Professor of Molecular and Cell Biology at the University of California, Berkeley, with affiliations in the Division of Genetics. His research focuses on epithelial architecture, tumor suppression mechanisms, and morphogenetic processes in Drosophila. Key projects explore cell polarity regulation, epithelial-tumor interactions, and biomechanical forces in tissue development. His lab uses genetic screens and live imaging to study how polarity defects drive malignancy and how tumors induce systemic pathologies like cachexia. Research interests include understanding how epithelial organization controls organ size, tumor progression, and host responses to cancer. His work bridges molecular cell biology with organismal physiology, leveraging Drosophila as a model system for translational insights into human diseases like cancer. Recent studies highlight roles of extracellular matrix stiffness in tissue elongation and systemic coagulopathy in tumor lethality. Publications emphasize mechanistic links between polarity proteins (Scribble module), endocytic trafficking, and oncogenic pathways. The lab’s tools include novel cell migration tracking methods and genetically engineered tumor models. While no formal student advising list is provided, his work suggests leadership in training graduate students and postdocs in developmental and cancer biology.
Charles P Emerson Jr is Professor of Cell and Developmental Biology and Neurology at University of Massachusetts Medical School (UMass Chan Medical School), where he serves as Director of the Wellstone Muscular Dystrophy Program. His academic appointments include positions in the T.H. Chan School of Medicine Department of Neurology (Division Wellstone Program), Department of NeuroNexus Institute, and Morningside Graduate School of Biomedical Sciences Department of Neuroscience. Dr. Emerson received his undergraduate education at Princeton University in Biology/Biochemistry and his PhD from the University of California, San Diego in Biology. His academic career includes faculty positions at the University of Virginia (where he advanced to Commonwealth Professor of Biology), Fox Chase Cancer Center, University of Pennsylvania School of Medicine (as Joseph Leidy Professor and Chair of Cell and Developmental Biology), and Boston Biomedical Research Institute. He joined UMass Chan Medical School in 2013. The Emerson Lab investigates skeletal muscle development, regeneration and disease with a focus on transcriptional networks and signaling pathways controlling skeletal muscle progenitors. Current research utilizes genome, molecular and stem cell technologies to understand muscle development in embryos and muscle repair in adults, with particular emphasis on human muscle biology and muscular dystrophies. The lab has pioneered iPSC modeling of human skeletal myogenesis and muscular dystrophy, developing innovative approaches for investigating genetic and epigenetic regulatory mechanisms. Analysis of Dr. Emerson's recent publications reveals a strong focus on facioscapulohumeral muscular dystrophy (FSHD) and limb girdle muscular dystrophies (LGMD), particularly using CRISPR gene editing, RNA therapeutics, and stem cell approaches. His work integrates molecular biology, stem cell technology, and disease modeling to develop novel therapeutic strategies for muscular dystrophies. Dr. Emerson's research has been generously supported by the NIH, including Career Development and Merit Awards, and directorship of an NIH Wellstone Muscular Dystrophy Cooperative Research Center. He has led NIH graduate and postdoctoral training programs in cell and developmental biology and has mentored numerous graduate students and postdoctoral fellows throughout his career. The Emerson Lab operates within the UMass Chan Wellstone Muscular Dystrophy Cooperative Research Center, maintaining highly collaborative relationships with academic and industry scientists, clinicians, and patient advocates. The lab has developed innovative human stem cell models, particularly iPSC technologies, to investigate skeletal muscle development and disease mechanisms, with ongoing projects focused on CRISPR gene correction, RNA therapeutics, and small molecule development for muscular dystrophies.
John Condeelis, PhD, is a renowned Professor in the Department of Cell Biology and Department of Surgery at Albert Einstein College of Medicine. He holds multiple leadership roles, including Director of Basic and Translational Research in Surgery, Co-Director of the Gruss Lipper Biophotonics Center, and Scientific Director of the Analytical Imaging Facility. His research focuses on cancer biology, optical physics, and cell migration, with a particular emphasis on tumor metastasis mechanisms. Dr. Condeelis pioneered multiphoton imaging technologies and discovered the tumor microenvironment of metastasis (TMEM), a key predictor of metastatic risk. His lab integrates advanced imaging with molecular biology to study how tumor cells interact with macrophages and blood vessels during dissemination. Research Interests: Dr. Condeelis investigates the dynamic interplay between tumor cells, macrophages, and the extracellular matrix using cutting-edge imaging techniques. His work elucidates mechanisms of invasion, intravasation, and metastatic colonization, with a focus on biomarkers like TMEM and MenaCalc. Recent studies explore racial disparities in metastasis and the impact of chemotherapy on tumor microenvironment composition. Key Contributions: Dr. Condeelis has authored over 300 papers, advancing understanding of metastatic pathways and developing diagnostic tools. His lab collaborates on clinical trials targeting metastasis drivers and optimizing therapies to minimize therapy-induced metastasis. He leads a multidisciplinary team including postdoctoral researchers, technicians, and students like Madeline Friedman.
Miyeko Mana is an Assistant Professor in the School of Life Sciences at Arizona State University, specializing in stem cell biology, cancer, and metabolic pathways. Her lab investigates how dietary factors influence stem cell behavior and oncogenic vulnerabilities, with a focus on intestinal and liver tissues. She holds a Ph.D. from the New York University Grossman School of Medicine and has been recognized with prestigious awards including the American Cancer Society Fellowship. Research interests include the interplay between diet, stem cell function, and epigenetic regulation, with applications to regenerative medicine and cancer therapy. Her work combines organoid models, metabolic studies, and molecular biology techniques to explore how high-fat diets or fasting impact stem cell niches and tumor initiation. Mana's recent publications highlight dietary effects on intestinal stemness, metabolic stress in liver pathology, and mechanobiological regulation of cell fate. Her lab actively recruits trainees and has produced notable alumni like Madeline Blatt (honors thesis) and Yesenia (Bio PhD candidate). Current projects aim to translate basic findings into clinical interventions targeting metabolic-cancer interfaces. Awards: NSF East Asia-Pacific Summer Institutes Fellow, NIH Developmental Genetics Training Award Labs/Teams: Laboratory of Stem Cell Regulation (manalabasu) Grants: NIH-supported studies on metabolic-stem cell interactions
Haakon Robin Skogseth is an Associate Professor at the Norwegian University of Science and Technology (NTNU), affiliated with the Department of Public Health and Nursing within the Faculty of Medicine and Health Sciences. His research focuses on prostate cancer biology, cancer metastasis mechanisms, and biobanking methodologies. Skogseth has contributed to optimizing tissue preservation techniques, identifying biomarkers, and studying gene expression changes in cancerous tissues. He holds a Doctoral Dissertation (2007) and Master's Thesis (2009), with early research rooted in plasminogen activator studies (2001). His work spans from foundational molecular biology to translational biobanking solutions, emphasizing clinical applications and public health implications. Research trends in his publications highlight advancements in biobanking protocols, prostate cancer biomarker discovery, and therapeutic target validation. He has explored the role of tyrosine kinase inhibitors and miRNA profiles in cancer progression, alongside epidemiological studies on fetal growth. Skogseth collaborates on projects like the Scandinavian SGA cohort and regional biobanking initiatives in Central Norway. His teaching includes the MDV6004 biobanking course, reflecting his expertise in both research and academic training.
Federico Corti is an Associate Research Scientist in the Department of Cardiovascular Medicine at Yale School of Medicine, Yale University. His research focuses on vascular biology, proteoglycan signaling, and the molecular mechanisms underlying endothelial cell function. Dr. Corti holds a PhD from the University of Siena (2010) and an MSc in Medicinal Chemistry from the same institution (2006). His work investigates syndecan proteins, VEGF receptor signaling, and their roles in vascular permeability, angiogenesis, and lymphatic development. Key contributions include identifying Syndecan-2's selective regulation of VEGF-induced vascular permeability and elucidating the role of Syndecan-4 in endothelial alignment and atheroprotective signaling. Recent studies explore anti-Syndecan 2 antibody treatments for reducing edema in CNV models. Dr. Corti collaborates with prominent researchers such as Martin Schwartz and Michael Simons, advancing translational research in cardiovascular and vascular biology. His findings have implications for treatments targeting vascular disorders, including ischemic stroke and diabetic complications.
Dr. Ian Ellis is a Senior Lecturer in Dentistry at the University of Dundee’s School of Dentistry. He holds multiple safety roles including Unit Biological Safety Officer, School Radiological Safety Officer, and membership in numerous safety committees at the school, university, and NHS levels. His research focuses on tumor cell motility, extracellular matrix interactions, cytokine effects, and signal transduction pathways in cancer metastasis. He teaches Cell Biology and Developmental Biology modules in dental programs and supervises PhD, MRes, and BMSc students. Ellis has contributed to over 50 peer-reviewed publications and actively participates in research projects investigating oral cancer mechanisms and regenerative therapies. His professional service includes roles as a UCU and DUCU Health and Safety Representative. Ellis has presented research at international conferences like the International Association of Dental Research and collaborates on projects such as studying mifepristone’s effects on oral cancer cells and Akt signaling pathways in metastasis.
Timothy Nottoli, PhD, is a Senior Research Scientist in the Department of Comparative Medicine at Yale University, and Co-Director of the Yale Genome Editing Center (YGEC). He holds a PhD from the University of California, Berkeley (1992) and a BA from the University of California, Santa Barbara (1985). His research focuses on genome editing, mouse models for disease mechanisms, and genetic regulation in developmental and evolutionary contexts. Dr. Nottoli collaborates extensively with investigators like James Noonan and Shuichi Ahsan, advancing studies in gene therapy, cardiovascular malformations, and genetic disorders such as systemic lupus erythematosus and microvillus inclusion disease. His work integrates CRISPR-based tools to engineer precise genetic modifications in mice, enabling disease modeling and therapeutic testing. Key projects include enhancing AsCas12a knock-in efficiency for immunogenetics studies and exploring evolutionary innovations in regulatory elements linked to developmental genes. His lab’s contributions span molecular biology, epigenetics, and translational medicine, with implications for personalized therapies and understanding genetic pathways. Dr. Nottoli’s academic roles include co-directing the YGEC, fostering interdisciplinary genome-editing initiatives. He has authored over 30 peer-reviewed publications, addressing topics like DNA repair mechanisms, hypertension pathophysiology, and genomic instability. His research emphasizes translational applications, such as developing mouse models to study human diseases and testing pharmacological interventions (e.g., isradipine for aldosteronism). Collaborative networks extend to departments like Neurosurgery and Genetics, reflecting his commitment to team science. Professional activities include advising on genomic tools and mentoring researchers in gene-editing techniques. His lab, part of the Yale School of Medicine, is located at the Anlyan Center. Contact details include an academic office phone (203.737.4325) and email for collaborations. No formal awards are listed, though his impactful contributions to genome editing are recognized through his publications and institutional roles.
Eleftherios (Terry) Sachlos is an Assistant Professor in the Department of Biology at York University's Faculty of Science. His research focuses on niche engineering of bone marrow and cancer stem cell microenvironments to regulate stem cell fate decisions, with applications in regenerative medicine and drug discovery. He leads the Stem Cell Engineering Lab, integrating tissue engineering and automation technologies. Education details are not provided in the text, but his affiliations include eligibility to supervise Biology Graduate Program students. His work bridges stem cell biology, cancer research, and translational medicine. Recent research emphasizes extracellular matrix interactions and drug screening platforms. Though no specific grants or awards are listed, his lab's innovative approaches to stem cell regulation suggest active research initiatives. The lab collaborates on regenerative medicine applications and automation in drug discovery.
Lisa Julian is an Assistant Professor in the Department of Biological Sciences at Simon Fraser University, holding a Canada Research Chair in Developmental Origins of Stem Cell Fate. Her research focuses on understanding how stem cell identity is regulated during development and how these processes influence tissue function and disease susceptibility, particularly in neural stem cells and the neural crest lineage. She employs human pluripotent stem cells (hPSCs), 3D organoids, and mouse models to study brain disorders and develop regenerative therapies. Education: BSc, MSc (University of Western Ontario); PhD (University of Ottawa). Her work integrates cutting-edge techniques like bioprinting, high-content imaging, and functional metabolic profiling to model diseases such as tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). Research interests include stem cell specification, disease modeling, and therapeutic target discovery. Her lab has pioneered organoid models for studying SARS-CoV-2 interactions and has identified HDAC inhibitors as potential treatments for LAM. Key contributions include uncovering how genetic mutations disrupt stem cell behavior and lead to tissue malformations. Award: 2019 Cardiopulmonary Best Abstract Award. Her lab’s work emphasizes translational research, aiming to bridge basic science and clinical applications through precision medicine and regenerative approaches.
Miklós Geiszt is a Professor of Physiology at Semmelweis University's Medical School since 2015. He holds dual roles as researcher and educator with over 30 years of academic service. His primary affiliation is the Department of Physiology, where he has held progressively senior roles including Assistant Professor (1997-2007) and Associate Professor (2007-2015). Education: MD (summa cum laude, 1993), PhD in Cellular & Molecular Physiology (1998) from Semmelweis University. Completed additional training at NIH's Laboratory of Host Defenses (1999-2002). Credentials include USMLE certifications and a Hungarian Unlimited Medical License. Research focuses on NADPH oxidase enzymes (Nox/Duox families), peroxidase functions, and redox biology. Key areas include collagen crosslinking mechanisms, endoplasmic reticulum redox regulation, and host defense systems. Over 30 peer-reviewed articles and 7 mentored PhD graduates demonstrate his impactful contributions. Award-winning educator with honors for tutoring excellence (2012), research distinction (Huzella Award 2019), and grants including Momentum Grant (2011). His work has advanced understanding of oxidative stress mechanisms in physiological and pathological conditions. Teaching spans 30+ years, including medical physiology instruction for Hungarian and international students. Maintains active laboratory research with collaborations at NIH and international conferences.
